ESO-T01

Phase 1Small molecule

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

ESO-T01 is one of 39 small molecule programs targeting Multiple Myeloma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple MyelomaRecruiting

Multiple MyelomaPhase 1

Recruiting

Competition

Competitive Landscape

258 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Belamaf

GSK

Phase 3

39 2

Venclexta

AbbVie

Phase 3

17 3

Keytruda

Merck & Co.

Phase 3

17 4

Opdivo

Bristol-Myers Squibb

Phase 3

11 5

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

28 6

Elranatamab

Pfizer

Phase 3

26 7

Cytosar

Teva

Phase 3

4 8

Busulfex

Akero Therapeutics

Phase 3

14 9

BLENREP

GGlaxo Dba Glaxosmithkline

Linvoseltamab

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Multiple Myeloma

NCT06791681

Clinical

Trials by Indication[1]

Multiple Myeloma2 trials

A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma

Recruiting·CChunrui Li·Phase 1·NCT06791681·24 enrolled

A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.

Suspended·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT06691685·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ESO-T01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ESO-T01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ESO-T01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Union Hospital, Tongji Medical College, Huazhong University of Science and Technology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

ESO-T01

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Multiple Myeloma2 trials

References

Drug Info

Quick Facts

Related News